Insulet Corporation Reports 30.7% Revenue Growth to $2.71 Billion in 2025

Insulet Corporation reported significant financial growth in its 2025 fiscal year, with total revenue reaching $2.71 billion, a 30.7% increase from $2.07 billion in 2024. The company's Omnipod product line, which includes the Omnipod 5 and Omnipod DASH systems, was the primary driver of this growth, contributing $2.67 billion to total revenue. U.S. sales of Omnipod products increased by 27.2% to $1.92 billion, while international sales surged by 44.1% to $754.3 million, reflecting strong demand and an expanding customer base. The company also reported a net income of $247.1 million, down from $418.3 million in the previous year, largely due to a $123.9 million loss on extinguishment of debt related to the repurchase of Convertible Senior Notes.

In terms of operational developments, Insulet's customer base grew to over 600,000 active Omnipod users globally by the end of 2025. The company launched Omnipod 5 in nine additional countries during the year, bringing its total availability to 19 countries. The Omnipod 5, which integrates with continuous glucose monitors (CGMs) and is controlled via a smartphone app, has been well-received, contributing to increased adoption rates. The company also reported a 38% increase in its workforce, bringing the total employee count to approximately 5,400, as it continues to expand its manufacturing capabilities and support its growing product lines.

Strategically, Insulet has made significant investments in research and development, with expenses rising to $301.1 million in 2025, up 37.1% from the previous year. This investment is aimed at enhancing the Omnipod platform and developing new products, including the next-generation Omnipod 6 and a fully closed-loop automated insulin delivery system for type 2 diabetes. The company also received FDA clearance for enhancements to the Omnipod 5 algorithm, which is expected to further improve user outcomes and drive sales.

Looking ahead, Insulet anticipates continued revenue growth in 2026, driven by the recurring revenue model associated with its disposable Pods and ongoing expansion in both U.S. and international markets. The company expects to benefit from the increasing adoption of Omnipod 5, particularly in the type 2 diabetes market, following the expanded FDA indication received in August 2024. However, Insulet also faces challenges, including potential impacts from macroeconomic conditions and competition in the diabetes management market, which could affect its growth trajectory.